دورية أكاديمية

Functional Interaction of Plasmacytoid Dendritic Cells with Multiple Myeloma Cells: A Therapeutic Target

التفاصيل البيبلوغرافية
العنوان: Functional Interaction of Plasmacytoid Dendritic Cells with Multiple Myeloma Cells: A Therapeutic Target
المؤلفون: Chauhan, Dharminder1 dharminder_chauhan@dfci.harvard.edu, Singh, Ajita V.1, Brahmandam, Mohan1, Carrasco, Ruben1, Bandi, Madhavi1, Hideshima, Teru1, Bianchi, Giada1, Podar, Klaus1, Tai, Yu-Tzu1, Mitsiades, Constantine1, Raje, Noopur1, Jaye, David L.2, Kumar, Shaji K.3, Richardson, Paul1, Munshi, Nikhil4, Anderson, Kenneth C.1 kenneth_anderson@dfci.harvard.edu
المصدر: Cancer Cell. Oct2009, Vol. 16 Issue 4, p309-323. 15p.
مصطلحات موضوعية: *DENDRITIC cells, *MULTIPLE myeloma treatment, *TARGETED drug delivery, *CARCINOGENESIS, *DRUG resistance in cancer cells, *BONE marrow, *IMMUNODEFICIENCY, *CANCER cell growth
مستخلص: Summary: Multiple myeloma (MM) remains incurable despite novel therapies, suggesting the need for further identification of factors mediating tumorigenesis and drug resistance. Using both in vitro and in vivo MM xenograft models, we show that plasmacytoid dendritic cells (pDCs) in the bone marrow (BM) microenvironment both mediate immune deficiency characteristic of MM and promote MM cell growth, survival, and drug resistance. Microarray, cell signaling, cytokine profile, and immunohistochemical analysis delineate the mechanisms mediating these sequelae. Although pDCs are resistant to novel therapies, targeting Toll-like receptors with CpG oligodeoxynucleotides both restores pDC immune function and abrogates pDC-induced MM cell growth. Our study therefore validates targeting pDC-MM interactions as a therapeutic strategy to overcome drug resistance in MM. [Copyright &y& Elsevier]
قاعدة البيانات: Academic Search Index
الوصف
تدمد:15356108
DOI:10.1016/j.ccr.2009.08.019